FDA Task Force Seeks Public Comments on Increasing Transparency with Regulated Industry

March 12, 2010, 10:52 am by FDA US Food & Drug Administration

As part of the final phase of its transparency initiative, the U.S. Food and Drug Administration is seeking comment from the public and other interested stakeholders on how the agency can increase transparency in its interactions with regulated industry.

Read the full article

More from FDA US Food & Drug Administration

FDA and industry reach agreement in principle on medical device user fees
FDA US Food & Drug Administration : February 1, 2012, 9:48 am
The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would

FDA approves Kalydeco to treat rare form of cystic fibrosis
FDA US Food & Drug Administration : January 31, 2012, 10:59 am
The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific

FDA takes action against New York cheese manufacturer
FDA US Food & Drug Administration : January 31, 2012, 10:13 am
The U.S. Food and Drug Administration is asking a federal court to prevent a New York cheese manufacturer from operating because of a history of unsanitary conditions and producing cheese in a

FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer
FDA US Food & Drug Administration : January 31, 2012, 5:29 am
The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today’s action also highlights an increase

FDA approves new treatment for most common type of skin cancer
FDA US Food & Drug Administration : January 30, 2012, 10:58 am
Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for